Research programme: bovine adrenal medulla 8 analogues - OKYO Pharma/Tufts Medical Center
Alternative Names: Bam8 analogues; Bam8-22 analoguesLatest Information Update: 28 Mar 2025
At a glance
- Originator OKYO Pharma
- Developer OKYO Pharma; Tufts Medical Center
- Class Anti-inflammatories; Eye disorder therapies; Lipids; Non-opioid analgesics; Peptides
- Mechanism of Action G protein-coupled receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Dry eyes; Neuropathic pain; Ocular inflammation; Ocular pain
Most Recent Events
- 28 Mar 2025 No recent reports of development identified for research development in Dry-eyes in United Kingdom
- 28 Mar 2025 No recent reports of development identified for research development in Ocular-inflammation in United Kingdom
- 28 Sep 2023 No recent reports of development identified for preclinical development in Neuropathic-pain in United Kingdom